Scarica l'app Stockscreener
3.89
9.12%
0.325
Dopo l'orario di chiusura:
3.90
0.010
+0.26%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché PYXS Giù?
Forum
Previsione
Pyxis Oncology Inc Borsa (PYXS) Ultime notizie
Pyxis Oncology files prospectus for 39.2M share sale by existing holders - scanx.trade
Pyxis Oncology (PYXS) awards director options at $3.12 - Stock Titan
Q3 EPS Estimates for Pyxis Oncology Raised by HC Wainwright - MarketBeat
Pyxis Oncology FY2030 EPS Forecast Reduced by HC Wainwright - MarketBeat
HC Wainwright Reiterates Buy Rating for Pyxis Oncology (NASDAQ:PYXS) - MarketBeat
symbol__ Stock Quote Price and Forecast - CNN
PYXS Q1 2026 Earnings: Modest EPS Beat Points to Cost Discipline for Clinical-Stage Oncology FirmDividend Earnings Report - vinanet.vn
Analysts Are Bullish on Top Healthcare Stocks: BridgeBio Pharma (BBIO), Pyxis Oncology (PYXS) - The Globe and Mail
Pyxis Oncology (PYXS) Gets a Buy from Wells Fargo - The Globe and Mail
Pyxis Oncology, Inc. (NASDAQ:PYXS) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Pyxis Oncology (PYXS) CEO receives 250,956-share performance-based option grant - Stock Titan
Pyxis Oncology Inc (NASDAQ: PYXS) Share Price, PYXS Stock News, PYXS Share Price & Updates - Kalkine
LifeSci Capital Maintains Pyxis Oncology(PYXS.US) With Buy Rating, Maintains Target Price $6 - Moomoo
Pyxis Oncology Faces Mounting Dilution Risk as Ongoing Equity Raises and Warrants Pressure Shareholder Value - TipRanks
Pyxis Oncology (NASDAQ:PYXS) Releases Quarterly Earnings Results, Misses Expectations By $0.06 EPS - MarketBeat
Pyxis Oncology Releases Q2 2026 Financial Results - AlphaStreet
Pyxis Oncology Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Pyxis Oncology Q2 loss widens 38%, misses EPS estimate - scanx.trade
Form 8K Pyxis Oncology Inc For: 13 August By Investing.com - Investing.com Nigeria
PYXS: MICVO demonstrates high efficacy and disease control in R/M HNSCC, with pivotal data due in 2026 - TradingView
Pyxis Oncology, Inc. Q2 2026: Revenue $0 EPS $(0.40) — 10-Q Summary - TradingView
Pyxis Oncology Reports $25.3 Million Second-Quarter Net Loss - Quiver Quantitative
Pyxis Oncology, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Pyxis Oncology Reports Second Quarter 2026 Financial Results and Advances MICVO Toward Key 2026 Clinical Milestones - The Manila Times
Pyxis Oncology 2Q Research and Development Expenses $16.1M >PYXS - Moomoo
Pyxis Oncology Q2 FY26 net loss widens to $25.3 million - Bitget
Pyxis Oncology (PYXS) Rises 7.4% to $3.04 as Biotech Buying Momentum BuildsQuality Factor - Vinanet
currently "more than watching" heheheh - Moomoo
Pyxis Oncology Inc expected to post a loss of 35 cents a shareEarnings Preview - TradingView
Pyxis Oncology (PYXS) Gains 2.68% as Clinical-Stage Biotech Finds Buying SupportDealer Delta - vinanet.vn
Pyxis Oncology Inc (PYXS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Pyxis Oncology Inc (PYXS) Stock News Today - TradingKey
Price to earnings forward of Pyxis Oncology, Inc. – NASDAQ:PYXS - TradingView
Price to sales forward of Pyxis Oncology, Inc. – NASDAQ:PYXS - TradingView
Pyxis Oncology (PYXS) Projected to Release Quarterly Earnings on Thursday - MarketBeat
Pyxis Oncology (NASDAQ:PYXS) Raised to Strong-Buy at Wells Fargo & Company - MarketBeat
PYXS Initiates Coverage On Wells Fargo -- Rating Set to Overweig - GuruFocus
Wells Fargo initiates Pyxis Oncology stock with overweight rating By Investing.com - Investing.com South Africa
Wells Fargo Initiates Pyxis Oncology at Overweight With $12 Price Target - marketscreener.com
Pyxis Oncology (PYXS) Slides 7.67% as Biotech Momentum Fades, Testing Key Support ZoneSuperTrend - vinanet.vn
PYXS|Pyxis Oncology Inc|Price:2.910|Chg%:+0.300 - TradingKey
Pyxis Oncology Inc (PYXS) Balance Sheet - TradingKey
Pyxis Oncology Inc (PYXS) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Pyxis Oncology Inc (PYXS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Pyxis Oncology Inc (PYXS) Institutional Confidence - TradingKey
Pyxis Oncology Inc (PYXS) Income Statement - TradingKey
Pyxis Oncology Inc (PYXS) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
PYXS|Pyxis Oncology Inc|Price:2.610|Chg%:-0.070 - TradingKey
Pyxis Oncology Inc (PYXS) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Pyxis Oncology Inc (PYXS) Valuation: PE, PB & Fair Value Analysis - TradingKey
Pyxis Oncology Inc (PYXS) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
PYXS stock trades steady as Pyxis Oncology highlights cash runway and clinical progress - Ad-hoc-news.de
PYXS Q1 2026 Earnings: Narrower Loss Per Share Surprises Market as Pipeline Progress ContinuesEarnings Acceleration Picks - vinanet.vn
Pyxis Oncology, Inc. (NASDAQ:PYXS) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Pyxis Oncology Q1 2026 Earnings: Narrower Loss Per Share Drives Positive Stock MovementSlow Growth Warning - dars.gov.et
Craig D Gordon Net Worth (2026) - GuruFocus
BIOTECHNOLOGY VALUE FUND L P's Strategic Acquisition in Pyxis Oncology Inc. - GuruFocus
Pyxis Oncology Q1 2026 Earnings: Narrower-Than-Expected Loss Drives Positive Stock ReactionEPS Growth Report - dars.gov.et
Pyxis Oncology: The Market Might Have Already Ruled On Micvotabart Pelidotin - Seeking Alpha
Pyxis Oncology (PYXS) Declines 7.87% as Stock Tests Key Support Near $2.34Percent Above MA - dars.gov.et
0.86%
0.31%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):